WCM Investment Management LLC Increases Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

WCM Investment Management LLC lifted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 49.1% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 202,213 shares of the biopharmaceutical company's stock after purchasing an additional 66,604 shares during the period. WCM Investment Management LLC owned 0.22% of Ultragenyx Pharmaceutical worth $7,648,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Smartleaf Asset Management LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 259.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 493 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 76.2% in the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 323 shares during the period. Aster Capital Management DIFC Ltd purchased a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $35,000. GF Fund Management CO. LTD. purchased a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $82,000. Finally, Quarry LP purchased a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $84,000. Hedge funds and other institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Trading Down 0.7%

Shares of RARE traded down $0.27 during midday trading on Friday, hitting $39.19. 685,292 shares of the company's stock traded hands, compared to its average volume of 839,148. Ultragenyx Pharmaceutical Inc. has a 1 year low of $29.59 and a 1 year high of $60.37. The firm's fifty day moving average is $36.72 and its 200-day moving average is $38.98. The stock has a market capitalization of $3.71 billion, a price-to-earnings ratio of -6.66 and a beta of 0.26.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative net margin of 93.04% and a negative return on equity of 186.49%. The business had revenue of $139.29 million for the quarter, compared to analysts' expectations of $145.98 million. During the same quarter in the prior year, the company posted ($2.03) EPS. The business's revenue for the quarter was up 28.0% on a year-over-year basis. On average, equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the company's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $37.39, for a total value of $89,922.95. Following the transaction, the director directly owned 15,344 shares of the company's stock, valued at $573,712.16. This represents a 13.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last ninety days, insiders sold 3,167 shares of company stock worth $118,824. Corporate insiders own 5.50% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on RARE shares. Piper Sandler lowered their price target on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a report on Monday, March 17th. Morgan Stanley upped their target price on Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. William Blair assumed coverage on Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They set an "outperform" rating and a $65.00 target price for the company. Guggenheim restated a "buy" rating and set a $64.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, June 20th. Finally, JPMorgan Chase & Co. upped their target price on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $87.00.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.